Cargando…

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

AIM: To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS: A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luchetti, Michele Maria, Benfaremo, Devis, Ciccia, Francesco, Bolognini, Laura, Ciferri, Monia, Farinelli, Alessia, Rossini, Matteo, Mosca, Piergiorgio, Triolo, Giovanni, Gabrielli, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656461/ https://www.ncbi.nlm.nih.gov/pubmed/29093622 http://dx.doi.org/10.3748/wjg.v23.i39.7139

Ejemplares similares

Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs
por: Benfaremo, Devis, et al.
Publicado: (2019)

Enteropathic Spondyloarthritis: From Diagnosis to Treatment
por: Peluso, Rosario, et al.
Publicado: (2013)

Isolated Aortitis Presenting with an Annoying Persistent Cough: A Case Report
por: Luchetti, Michele Maria, et al.
Publicado: (2016)

Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
por: Benfaremo, Devis, et al.
Publicado: (2018)

Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis
por: Pott, Nina Mee, et al.
Publicado: (2022)

Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy
por: Benfaremo, Devis, et al.
Publicado: (2021)

Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
por: Benfaremo, Devis, et al.
Publicado: (2019)

Diagnosis and management of leukocytoclastic vasculitis
por: Fraticelli, Paolo, et al.
Publicado: (2021)

63. A case of enteropathic arthritis: or is it?
por: Al-Zaza, Magda, et al.
Publicado: (2018)

Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study
por: Conigliaro, Paola, et al.
Publicado: (2021)

Inflammatory Bowel Disease: Focus on Enteropathic Arthritis and Therapy
por: Barkhodari, Amir, et al.
Publicado: (2022)

Etanercept in the treatment of recalcitrant enteropathic arthritis: a case report
por: Mohamed Said, Mohd Shahrir, et al.
Publicado: (2012)

A young man with persistent dyspepsia: the unexpected virtue of proton-pump inhibitors
por: Paolo, Fraticelli, et al.
Publicado: (2018)

Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis
por: Vounotrypidis, Periklis, et al.
Publicado: (2013)

Yersinia pseudotuberculosis enterocolitis mimicking enteropathic γδ T-cell lymphoma with abnormal clonality
por: Imataki, Osamu, et al.
Publicado: (2014)

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
por: Baker, Rahaf, et al.
Publicado: (2018)

Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis
por: Zhao, Sizheng, et al.
Publicado: (2016)

Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis
por: Coulter, Elaine H., et al.
Publicado: (2019)

Organisation and content of supervised group exercise for people with axial spondyloarthritis in The Netherlands
por: Hilberdink, Bas, et al.
Publicado: (2020)

Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis
por: Sariyildiz, Aylin, et al.
Publicado: (2023)

Axial spondyloarthritis and inflammatory bowel disease: association between disease activity and endothelial dysfunction markers
por: Przepiera-Będzak, Hanna, et al.
Publicado: (2021)

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
por: Hiltunen, J., et al.
Publicado: (2021)

Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease
por: Tschulena, Ulrich, et al.
Publicado: (2011)

Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia
por: Sheikh, Alaullah, et al.
Publicado: (2022)

Analyzing web searches for axial spondyloarthritis in Germany: a novel approach to exploring interests and unmet needs
por: Berr, Kristina, et al.
Publicado: (2023)

Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab
por: Otsuka, Akiyo, et al.
Publicado: (2015)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice
por: Calvo Moya, Marta, et al.
Publicado: (2023)

Multidisciplinary working in the management of axial and peripheral spondyloarthritis
por: Gudu, Tania, et al.
Publicado: (2020)

Role of Subclinical Gut Inflammation in the Pathogenesis of Spondyloarthritis
por: Rizzo, Aroldo, et al.
Publicado: (2018)

Novel immune cell phenotypes in spondyloarthritis pathogenesis
por: Mauro, Daniele, et al.
Publicado: (2021)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021)

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
por: Sirmai, Laura, et al.
Publicado: (2022)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Student-led clinics and ePROs to accelerate diagnosis and treatment of patients with axial spondyloarthritis: results from a prospective pilot study
por: von Rohr, Sophie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qa3n61fa2nd152vrkj5njo76t1